Tucson’s News 13 recently highlighted Precision Epigenomic’s groundbreaking work developing EPISEEK™, a multi-cancer early detection blood test. The segment focused on EPISEEK that looks for signals shared by more than 50 types of cancer through a simple blood draw, potentially leading to earlier diagnoses, more effective treatments, and reduced financial burdens for patients.
Our cofounder and CEO, Mark Nelson, emphasized the importance of early detection, particularly for cancers that currently lack effective screening options. The news feature also explored the origins of EPISEEK™, which stemmed from research at the University of Arizona, and our global aspirations to expand access to the test. While currently retailing at $699, Precision Epigenomics is working on making the test even more affordable to increase accessibility.
Read the full article here.